RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
NCT05127590
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
DRUG:
RBN-2397
Sponsor
Ribon Therapeutics, Inc.